Preview

Онкоурология

Расширенный поиск

Современные подходы к лечению почечно-клеточного рака

https://doi.org/10.17650/1726-9776-2006-2-1-17-25

Полный текст:

Об авторах

Зия Киркали
Dokuz Eylul University School of Medicine Department of Urology
Турция


A. Эрдем Канда
Dokuz Eylul University School of Medicine Department of Urology
Турция


Список литературы

1. Jacqmin D., van Poppel H., Kirkali Z., Mickisch G. Renal cancer // Eur. Urol. — 2001;39:361—369.

2. Kirkali Z., Yorukoglu K. Premalignant lesions in the kidney // Scientific World J. — 2001;1:855—867.

3. Pehlivan S., Koyuncuoglu M., Pehlivan M. et al. Premalignant lesions of the kidney share the same genetics changes as conventional renal cell carcinoma // World J. Urol. — 2004;22(2):120—123.

4. Kirkali Z., Lekili M. Renal cell carcinoma: new prognostic factors? // Curr. Opin. Urol. — 2003;13(6):433—438.

5. Kirkali Z. Limits of cure by surgery in renal cell carcinoma / In Kurth K.H., Mickisch G.H., Schroeder F.H. eds // Renal, Bladder and Prostate Cancer, an Update. Bath: Parthenon Publishing Group. — 1999:15—22.

6. Lam J.S., Shvarts O., Pantuck A.J. Changing concepts in the surgical management of renal cell carcinoma // Eur. Urol. — 2004;45(6):692—705.

7. Tsui K.H., Shvarts O., Barbaric Z. et al. Is adrenalectomy a necessary component of radical nephrectomy? UCLA experience with 511 radical nephrectomies // J. Urol. — 2000;163:437—441.

8. Blom J.H., van Poppel H., Marechal J.M. et al. Radical nephrectomy with and without lymph node dissection: Preliminary results of the EORTC Randomized Phase III Protocol 30881 // Eur. Urol. — 1999;36:570—575.

9. Minervini A., Lilas L., Morelli G. et al. Regional lymph node dissection in the treatment of renal cell carcinoma: is it useful in patients with no suspected adenopathy before or during surgery? // BJU Int. — 2001;88(3):169—172.

10. Fenn N.J., Gill I.S. The expanding indications for laparoscopic radical nephrectomy // BJU Int. — 2004;94(6):761—765.

11. Portis A.J., Yan Y., Landman J. et al. Long term follow up after laparoscopic radical nephrectomy // J. Urol. — 2002;167:1257—1262.

12. Desai M.M., Strzempkowski B., Matin S.F. et al. Prospective randomized comparison of transperitoneal versus retroperitoneal laparoscopic radical nephrectomy // J. Urol. — 2005;173(1):38—41.

13. Shuford M.D., McDougall E.M., Chang S.S. et al. Complications of contemporary radical nephrectomy: compari son of open vs. laparoscopic approach // Urol. Oncol. — 2004;22(2):121—126.

14. Van Poppel H., Baert L.V. Nephron sparing surgery / In Petrovich Z., Baert L., Brady L.W. eds, Carcinoma of the Kidney and Testis, Rare Urological Malignancies. Innovations in Management. — Berlin, Heidelberg: Springer—Verlag. — 1999:79—93.

15. Nieder A.M., Taneja S.S. The role of partial nephrectomy for renal cell carcinoma in contemporary practice // Urol. Clin. North. Am. — 2003;30(3):529—542.

16. Hafez K.S., Fergany A.F., Novick A.C. Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging // J. Urol. — 1999;162(6):1930—1933.

17. Lerner S.E., Hawkins C.A., Blute M.L. et al. Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery // J. Urol. — 1996;155(6):1868—1873.

18. Fergany A.F., Hafez K.S., Novick A.C. Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup // J. Urol. — 2000;163(2):442—445.

19. Lee C.T., Katz J., Shi W. et al. Surgical management of renal tumors 4 cm. or less in a contemporary cohort // J. Urol. — 2000;163(3):730—736.

20. Belldegrun A., Tsui K.H., deKernion J.B., Smith R.B. Efficacy of nephron-sparing surgery for renal cell carcinoma: analysis based on the new 1997 tumor-nodemetastasis staging system // J. Clin. Oncol. — 1999;17(9):2868—2875.

21. Thrasher J.B., Robertson J.E., Paulson D.F. Expanding indications for conservative renal surgery in renal cell carcinoma // Urology. — 1994;43(2):160—168.

22. Vermooten V. Indications for conservative surgery in certain renal tumors: a study based on the growth pattern of the cell carcinoma // J. Urol. — 1950;64(2):200—208.

23. Hafez K.S., Novick A.C., Butler B.P. Management of small solitary unilateral renal cell carcinomas: impact of central versus peripheral tumor location // J. Urol. — 1998;159(4):1156—1160.

24. Blackley S.K., Ladaga L., Woolfitt R.A., Schellhammer P.F. Ex situ study of the effectiveness of enucleation in patients with renal cell carcinoma // J. Urol. — 1988;140(1):6—10.

25. Robson C.J. Radical nephrectomy for renal cell carcinoma // J. Urol. — 1963;89:37—42.

26. McKiernan J., Simmons R., Katz J., Russo P. Natural history of chronic renal insufficiency after partial and radical nephrectomy // Urology. — 2002;59(6):816—820.

27. Lau W.K., Blute M.L., Weaver A.L. et al. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney // Mayo Clin. Proc. — 2000;75(12):1236—1242.

28. Novick A.C. Laparoscopic and partial nephrectomy // Clin. Cancer. Res. — 2004; 15;10(18 Pt 2):6322S—6327S.

29. Gill I.S., Matin S.F., Desai M.M. et al. Comparative analysis of laparoscopic versus open partial nephrectomy for renal tumors in 200 patients // J. Urol. — 2003;170(1):64—68.

30. Seifman B.D., Hollenbeck B.K., Wolf J.S. Jr. Laparoscopic nephron-sparing surgery for a renal mass: 1-year minimum follow-up // J. Endourol. — 2004;18(8):783—786.

31. Hwang J.J., Walther M.M. Update on minimally invasive approaches to kidney tumors // Curr. Urol. Rep. — 2004;5(1):13—18.

32. Cestari A., Guazzoni G., dell'Acqua V. et al. Laparoscopic cryoablation of solid renal masses: intermediate term followup // J. Urol. — 2004;172(4 Pt 1):1267—1270.

33. Kirkali Z., Tuzel E., Mungan M.U. Recent advances in kidney cancer and metastatic disease // BJU Int. — 2001;88(8):818—824.

34. Huland E., Heinzer H. Renal cell carcinoma — innovative medical treatments // Curr. Opin. Urol. — 2004;14(4):239—244.

35. Bukowski R.M. Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma // Semin. Oncol. — 2000;27:204—212.

36. McDermott D.F., Regan M.M., Clark J.I. et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma // J. Clin. Oncol. — 2005; 1;23(1):133—141

37. Waters J.S., Moss C., Pyle L. et al. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma // Br. J. Cancer. — 2004; 15;91(10):1763—1768.

38. Nanus D.M., Garino A., Milowsky M.I. et al. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma // Cancer. — 2004; 1;101(7):1545—1551.

39. Lipton A., Colombo-Berra A., Bukowski R.M. et al. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid // Clin. Cancer Res. — 2004; 15;10(18 Pt 2):6397—6403.

40. Aass N., De Mulder P.H., Mickisch G.H. et al. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951) // J. Clin. Oncol. — 2005; 20;23(18):4172—4178.

41. Rackley R., Novick A., Klein E. et al. The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma // J. Urol. — 1994;152:1399—1403.

42. Mickisch G.H., Garin A., Madej M., Sylvester R. Tumour nephrectomy plus interferon-a is superior to interferon-alone in metastatic renal cell carcinoma // J. Urol. — 2000; 163: 778A.

43. Staehler G., Brkovic D. The role of radical surgery for renal cell carcinoma with extension into the vena cava // J. Urol. — 2000;163:1671—1675.

44. Stadler W.M., Kuzel T., Shapiro C. et al. A multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal cell carcinoma // J. Clin. Oncol. — 1999;17:2541—2545.

45. De Mulder P.H., van Herpen C.M., Mulders P.A. Current treatment of renal cell carcinoma // Ann. Oncol. — 2004;15, Suppl. 4: 319—328.

46. Oosterwijk E., Divgi C.R., Brouwers A. et al. Monoclonal antibody-based therapy for renal cell carcinoma // Urol. Clin. North Am. — 2003;30(3):623—631.


Для цитирования:


Киркали З., Эрдем Канда A. Современные подходы к лечению почечно-клеточного рака. Онкоурология. 2006;2(1):17-25. https://doi.org/10.17650/1726-9776-2006-2-1-17-25

For citation:


Kirkali Z., Erdem Canda A. Modern Approaches to the Treatment of Renal Cell Carcinoma. Cancer Urology. 2006;2(1):17-25. (In Russ.) https://doi.org/10.17650/1726-9776-2006-2-1-17-25

Просмотров: 29


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)
X